Kinome expression profiling identifies IKBKE as a predictor of overall survival in clear cell renal cell carcinoma patients

Carcinogenesis

Volumn 33, Issue 4, 2012, Pages 799-803

  Hildebrandt, Michelle A T ^a   Tan, Weiqi ^a   Tamboli, Pheroze ^a   Huang, Maosheng ^a   Ye, Yuanqing ^a   Lin, Jie ^a   Lee, Ju Seog ^a   Wood, Christopher G ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE EPSILON;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLEAR CELL RENAL CELL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE REPLICATION; HUMAN; HUMAN TISSUE; INTERVIEW; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

EID: 84859596111     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs018     Document Type: Article

References (33)

1. Manning, G. et al. (2002) The protein kinase complement of the human genome. Science, 298, 1912-1934.
2. Brognard, J. et al. (2011) Protein kinase signaling networks in cancer. Curr. Opin. Genet. Dev., 21, 4-11.
3. Linehan, W. M. et al. (2010) Molecular diagnosis and therapy of kidney cancer. Annu. Rev. Med., 61, 329-343.
4. Jemal, A. et al. (2010) Cancer statistics, 2010. CACancer J. Clin., 60, 277-300.
5. Howlader, N. et al. (2011) SEER Cancer Statistics Review, 1975-2008. National Cancer Institute, Bethesda, MD.
6. Porta, C. et al. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Med. Oncol, e-Pub 2011 July 7. DOI: 10. 1007/s12032-011-0016-8.
7. Reich, M. et al. (2006) GenePattern 2. 0. Nat. Genet., 38, 500-501.
8. Cohen, P. (2002) Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov., 1, 309-315.
9. Shimada, T. et al. (1999) IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. Int. Immunol., 11, 1357-1362.
10. Peters, R. T. et al. (2000) IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol. Cell, 5, 513-522.
11. Adli, M. et al. (2006) IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J. Biol. Chem., 281, 26976-26984.
12. Harris, J. et al. (2006) Nuclear accumulation of cRel following C-terminal phosphorylation by TBK1/IKK epsilon. J. Immunol., 177, 2527-2535.
13. Sharma, S. et al. (2003) Triggering the interferon antiviral response through an IKK-related pathway. Science, 300, 1148-1151.
14. Fitzgerald, K. A. et al. (2003) IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol., 4, 491-496.
15. Chiang, S. H. et al. (2009) The protein kinase IKKepsilon regulates energy balance in obese mice. Cell, 138, 961-975.
16. Boehm, J. S. et al. (2007) Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell, 129, 1065-1079.
17. Guo, J. P. et al. (2009) Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am. J. Pathol., 175, 324-333.
18. Guo, J. P. et al. (2010) IKKepsilon phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer. J. Biol. Chem., 285, 3676-3684.
19. Eddy, S. F. et al. (2005) Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells. Cancer Res., 65, 11375-11383.
20. Guan, H. et al. (2011) IKBKE is over-expressed in glioma and contributes to resistance of glioma cells to apoptosis via activating NF-kappaB. J. Pathol., 223, 436-445.
21. Colas, E. et al. (2011) Molecular markers of endometrial carcinoma detected in uterine aspirates. Int. J. Cancer, 129, 2435-2444.
22. Zhou, L. et al. (2011) Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27. 3 associate with clear cell renal cell carcinoma. PLoS One, 5, e15224.
23. Deb, T. B. et al. (2011) Pnck induces ligand-independent EGFR degradation by probable perturbation of the Hsp90 chaperone complex. Am. J. Physiol. Cell Physiol., 300, C1139-C1154.
24. Hudes, G. R. et al. (2009) Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin. Oncol., 36 (suppl. 3), S26-S36.
25. Xie, X. et al. (2011) IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc. Natl Acad. Sci. USA, 108, 6474-6479.
26. Holland, W. S. et al. (2012) Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother. Pharmacol., 69, 185-194.
27. Takahashi, M. et al. (2001) Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc. Natl Acad. Sci. USA, 98, 9754-9759.
28. Vasselli, J. R. et al. (2003) Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc. Natl Acad. Sci. USA, 100, 6958-6963.
29. Jones, J. et al. (2005) Gene signatures of progression and metastasis in renal cell cancer. Clin. Cancer Res., 11, 5730-5739.
30. Kosari, F. et al. (2005) Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin. Cancer Res., 11, 5128-5139.
31. Sultmann, H. et al. (2005) Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin. Cancer Res., 11, 646-655.
32. Zhao, H. et al. (2006) Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med., 3, e13.
33. Nogueira, M. et al. (2008) Molecular markers for predicting prognosis of renal cell carcinoma. Urol. Oncol., 26, 113-124.